We are live on ! Find out more
BBH icon

VanEck Biotech ETF

84 hedge funds and large institutions have $67.4M invested in VanEck Biotech ETF in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more call options, than puts

Call options by funds: $777K | Put options by funds: $689K

1% more funds holding

Funds holding: 83 → 84 (+1)

8% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 13

0.41% less ownership

Funds ownership: 18.27% → 17.86% (-0.41%)

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

30% less capital inflows, than outflows

Capital inflows: $9.8M | Capital outflows: $14M

Holders
84
Holders Change
+1
Holders Change %
+1.2%
% of All Funds
1.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
20
Reduced
22
Closed
13
Calls
$777​K
Puts
$689​K
Net Calls
+$88​K
Net Calls Change
-⁠$1.37​M

BBH Hedge Fund Activity: Q4 2018 in Review

84 of the 4,507 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2018, worth a combined $67.4M — down 23% from $87M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new BBH positions and 13 closed out — a net gain of 1 holder — while 20 added to existing stakes and 22 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $2.15M. The largest seller was Susquehanna International Group, cutting an estimated $4.25M.

  • 84 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2018, up from 83 in Q3 2018.
  • Funds reported $67.4M of VanEck Biotech ETF stock for Q4 2018, down 23% quarter-over-quarter.
  • 14 funds opened new VanEck Biotech ETF positions in Q4 2018 and 13 closed out, a net change of +1 holder.
  • The largest VanEck Biotech ETF buyer in Q4 2018 was Citadel Advisors, an estimated $2.15M added.
  • The largest VanEck Biotech ETF seller in Q4 2018 was Susquehanna International Group, an estimated $4.25M sold.

Based on aggregated 13F filings for Q4 2018.